Patent · US Active

Chirally-enriched double-stranded RNA agents

US11597932B2 · kind B2 · utility

3Cited by

0References

24Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Muthiah Manoharan · Carlsbad, US
Nate TANEJA · Cambridge, US
Hartmut Ingo JAHNS · Cambridge, US
Shigeo Matsuda · Cambridge, US
Klaus Charisse · Acton, US
Guo He · Lexington, US
Jayaprakash K. Nair · Cambridge, US
Christopher BROWN · Cambridge, US
Mark K. Schlegel · Cambridge, US
Vasant Jadhav · Cambridge, US
Martin Maier · Cambridge, US

Key dates

Filing date	Dec 21, 2018
Grant date	Mar 7, 2023
Priority date	—
Expiry date	Jan 20, 2039

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2320/51
WIPO fieldBiotechnology
WIPO sectorChemistry

Abstract

The present invention relates to a chirally-modified dsRNA agent capable of inhibiting the expression of a target gene. The sense and antisense strands of chirally-modified dsRNA agent independently or in combination comprises one or more site specific-site specific/position specific, chirally-modified internucleotide linkages.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.